

Supplementary Table 2. Baseline clinical and biochemical characteristic of study subjects based on baseline serum uric acid quartile categories and both sexes according to incident metabolic syndrome: male

Characteristic	Percent changes in serum uric acid (not incident MetS in male, n=5,682)				Percent changes in serum uric acid (incident MetS in male, n=2,012)					
	Quartile 1 (≤-9.1%, n=1,382)	Quartile 2 (-9.0% to -0.1%, n=1,386)	Quartile 3 (0% to 8.2%, n=1,423)	Quartile 4 (≥8.3%, n=1,491)	P value	Quartile 1 (≤-9.1%, n=545)	Quartile 2 (-9.0% to -0.1%, n=544)	Quartile 3 (0% to 8.2%, n=485)	Quartile 4 (≥8.3%, n=438)	P value
Age, yr	52.8±8.4	51.7±8.2	51.2±8.5	51.0±8.3	0.000	52.5±8.0	51.9±7.6	51.3±7.6	51.5±8.6	0.025
Smoking status					0.000					0.090
Current smoker	316 (22.9)	315 (22.7)	379 (26.6)	430 (28.8)		162 (29.7)	178 (32.7)	138 (28.5)	160 (36.5)	
Ex-smoker	695 (50.3)	652 (47.0)	626 (44.0)	642 (43.1)		263 (48.3)	233 (42.8)	237 (48.9)	184 (42.0)	
Non-smoker	371 (26.8)	419 (30.2)	418 (29.4)	419 (28.1)		120 (22.0)	133 (24.4)	110 (22.7)	94 (21.5)	
BMI, kg/m ²	23.6±2.2	23.8±2.1	23.5±2.3	23.4±2.1	0.012	25.1±2.1	25.2±2.0	25.3±2.1	25.0±2.1	0.822
Waist circumference, cm	84.8±5.9	85.2±5.8	84.2±6.2	83.9±6.1	0.000	89.3±5.8	89.6±5.6	89.5±5.9	88.2±5.7	0.010
Fat-free mass, %	80.2±4.5	79.7±4.6	79.9±4.8	79.8±6.4	0.090	78.2±4.2	78.2±4.1	77.7±4.0	77.8±4.0	0.056
Systolic BP, mm Hg	110.9±13.9	111.3±13.6	111.9±13.7	113.3±14.3	0.000	115.0±13.6	115.2±12.8	114.4±12.8	115.6±13.4	0.757
Diastolic BP, mm Hg	69.3±9.5	69.9±9.5	70.1±9.6	70.8±9.9	0.000	72.5±8.8	71.9±9.0	71.7±8.9	72.9±8.7	0.656
eGFR, mL/min/1.73 m ²	86.4±11.3	87.1±11.1	88.5±11.6	89.7±11.7	0.000	86.8±10.9	86.4±11.2	88.1±12.1	90.0±12.2	0.000
Fasting glucose, mg/dL	88.7±12.3	88.7±11.5	89.3±13.8	90.6±16.9	0.000	92.5±15.0	92.2±13.0	92.1±13.3	94.2±16.6	0.120
Fasting insulin, μU/mL ^a	7.6 (5.9-9.7)	7.8 (6.1-10.0)	7.6 (5.9-9.5)	7.7 (6.0-9.7)	0.120	9.0 (6.9-11.4)	8.5 (6.9-10.9)	9.3 (7.1-11.5)	8.9 (7.1-11.6)	0.110
HOMA-IR ^a	1.7 (1.2-2.2)	1.7 (1.3-2.3)	1.6 (1.3-2.1)	1.7 (1.3-2.2)	0.073	2.1 (1.5-2.6)	1.9 (1.5-2.5)	2.1 (1.6-2.7)	2.1 (1.6-2.7)	0.133
Total cholesterol, mg/dL	189.4±30.8	189.5±30.1	188.3±30.0	187.5±29.8	0.052	194.0±30.9	190.6±30.4	189.7±31.0	188.8±30.6	0.006
TG, mg/dL	100.0 (76.0-133.0)	100.0 (77.0-134.0)	100.0 (76.0-133.0)	105.0 (79.0-135.0)	0.028	129.0 (100.0-174.0)	135.0 (106.0-180.5)	134.0 (106.0-170.0)	136.0 (104.0-186.0)	0.321
LDL-C, mg/dL	124.7±28.0	124.8±27.5	123.4±26.8	121.7±26.6	0.001	131.2±28.4	128.4±27.0	126.8±27.7	123.4±28.6	0.000
HDL-C, mg/dL	58.0±12.8	57.2±12.1	57.0±12.2	56.6±12.1	0.002	52.1±10.2	51.0±10.7	50.3±9.8	51.9±11.2	0.415
hs-CRP, mg/L	0.1±0.3	0.1±0.4	0.1±0.3	0.1±0.4	0.803	0.1±0.2	0.1±0.3	0.2±0.8	0.2±0.4	0.377
Baseline SUA, mg/dL	6.1±1.2	5.9±1.0	5.7±1.0	5.3±1.0	0.000	6.4±1.3	6.1±1.2	5.9±1.1	5.5±1.1	0.000
Change in SUA, %	-16.5±6.3	-4.9±2.3	3.5±2.6	18.3±9.5	0.000	-15.7±5.8	-4.8±2.3	3.4±2.6	18.1±9.2	0.000

Values are presented as mean ± standard deviation, number (%), or median (interquartile range). Characteristics of the study population according to the serum uric acid quartile were compared using one-way analysis of variance (ANOVA) or Kruskal-Wallis test for continuous variables and chi-square test for categorical variables. MetS, metabolic syndrome; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HOMA-IR, homeostasis model assessment index for insulin resistance; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; SUA, serum uric acid. ^an=5,188 male.